What is the prevalence of hyposomatotropism (growth hormone deficiency [GHD])?

Updated: Jan 24, 2019
  • Author: Sunil Kumar Sinha, MD; Chief Editor: Robert P Hoffman, MD  more...
  • Print

The prevalence of hyposomatotropism (growth hormone deficiency ) is estimated to be between 1 in 4000 and 1 in 10,000. [33] An estimated 6,000 adults are diagnosed with growth hormone (GH) deficiency every year in the United States. Adult GH deficiency has been estimated to affect 1 in 100,000 people annually, whereas its incidence is approximately 2 cases per 100,000 population when childhood-onset GH deficiency patients are considered. About 15-20% of the cases represent the transition of childhood GH deficiency into adulthood. [28]

A racial ascertainment bias may be noted. Demographic and diagnostic features of GHD in children in the United States reveal that black children with idiopathic GHD are shorter than white children are at the time of diagnosis. The low overall representation of black children in the population with GHD (6%) compared with their representation in the at-risk population (12.9%) also suggests an ascertainment bias between the races.

A male ascertainment bias may be observed. The predominance of GHD diagnosed in boys in the United States and the observation that girls with idiopathic GHD are comparatively shorter than boys at the time of diagnosis suggest a sex-based ascertainment bias.

Mortality in children with growth hormone deficiency is due almost entirely to other pituitary hormone deficiencies. [34]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!